


## Simmitecan hydrochloride

<b>Cat. No.:</b>	HY-107133
<b>CAS No.:</b>	1247847-78-4
<b>Molecular Formula:</b>	C <sub>34</sub> H <sub>39</sub> ClN <sub>4</sub> O <sub>6</sub>
<b>Molecular Weight:</b>	635.15
<b>Target:</b>	Topoisomerase; Cytochrome P450
<b>Pathway:</b>	Cell Cycle/DNA Damage; Metabolic Enzyme/Protease
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	Simmitecan hydrochloride, a 9-substituted lipophilic Camptothecin (HY-16560) derivative, is a potent topoisomerase I inhibitor. Simmitecan hydrochloride is an anticancer agent <sup>[1][2]</sup> .
<b>In Vitro</b>	Simmitecan hydrochloride weak inhibitory effects on CYP2D6 (IC <sub>50</sub> : 32.9 μM) and moderate inhibitory effects on CYP3A4 (IC <sub>50</sub> : 8.95 μM) <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
<b>In Vivo</b>	Simmitecan hydrochloride (3.75, 7.5 and 15 mg/kg, i.v. bolus) shows mean elimination half-life t <sub>1/2</sub> of approximately 1.4 h in SD rats <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

[1]. Rini B, et al. A phase I/II study of lenalidomide in combination with sunitinib in patients with advanced or metastatic renal cell carcinoma. *Ann Oncol.* 2014 Sep;25(9):1794-1799.

[2]. Hu ZY, et al. Pharmacokinetic evaluation of the anticancer prodrug simmitecan in different experimental animals. *Acta Pharmacol Sin.* 2013 Nov;34(11):1437-48.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA